These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28584936)

  • 1. A Review of Nitric Oxide for the Treatment of Glaucomatous Disease.
    Aliancy J; Stamer WD; Wirostko B
    Ophthalmol Ther; 2017 Dec; 6(2):221-232. PubMed ID: 28584936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
    Fingeret M; Gaddie IB; Bloomenstein M
    Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy.
    Addis VM; Miller-Ellis E
    Clin Ophthalmol; 2018; 12():2649-2657. PubMed ID: 30587912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies.
    Sharif NA
    Front Pharmacol; 2021; 12():729249. PubMed ID: 34603044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
    Cavet ME; DeCory HH
    J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide donating anti-glaucoma drugs: advances and prospects.
    Mao YJ; Wu JB; Yang ZQ; Zhang YH; Huang ZJ
    Chin J Nat Med; 2020 Apr; 18(4):275-283. PubMed ID: 32402405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New considerations for the clinical efficacy of old and new topical glaucoma medications.
    MacIver S; Stout N; Ricci O
    Clin Exp Optom; 2021 Apr; 104(3):350-366. PubMed ID: 33725467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
    Araie M; Sforzolini BS; Vittitow J; Weinreb RN
    Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.
    Rao PV; Pattabiraman PP; Kopczynski C
    Exp Eye Res; 2017 May; 158():23-32. PubMed ID: 27593914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide (NO): an emerging target for the treatment of glaucoma.
    Cavet ME; Vittitow JL; Impagnatiello F; Ongini E; Bastia E
    Invest Ophthalmol Vis Sci; 2014 Aug; 55(8):5005-15. PubMed ID: 25125670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanylate cyclase activators, cell volume changes and IOP reduction.
    Ellis DZ
    Cell Physiol Biochem; 2011; 28(6):1145-54. PubMed ID: 22179003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma.
    Patel PD; Chen YL; Kasetti RB; Maddineni P; Mayhew W; Millar JC; Ellis DZ; Sonkusare SK; Zode GS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33853948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: challenges of dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine.
    Babizhayev MA
    Fundam Clin Pharmacol; 2012 Feb; 26(1):86-117. PubMed ID: 21883446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen dysregulation, intraocular pressure, and glaucoma risk.
    Youngblood H; Schoenlein PV; Pasquale LR; Stamer WD; Liu Y
    Exp Eye Res; 2023 Dec; 237():109725. PubMed ID: 37956940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: Pitfalls, promises and what lies ahead?
    Prasanna G; Li B; Mogi M; Rice DS
    Eur J Pharmacol; 2016 Sep; 787():47-56. PubMed ID: 26948313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
    Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
    Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.